Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691184 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis
A Phase 1 study of Onychomycosis/Onycholysis and Tinea Pedis, sponsored by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT00691184 is a Phase 1 study of Onychomycosis/Onycholysis and Tinea Pedis that has completed, run by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.). The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00691184, a Phase 1 study of Onychomycosis/Onycholysis and Tinea Pedis, has completed, sponsored by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the safety and pharmacokinetics of 10 % terbinafine hydrogen chloride (HCl) nail lacquer wre investigated by comparison with vehicle control and 1% terbinafine cream
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Terbinafine Hydrochloride
- DRUG Terbinafine
Study Locations (1)
New Jersey
- TKL Research Inc. - Paramus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691184
The ClinicalTrials.gov registry entry for NCT00691184 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Onychomycosis/Onycholysis and Tinea Pedis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00691184 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00691184 about?
NCT00691184 is a clinical study titled "Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis". In this study, the safety and pharmacokinetics of 10 % terbinafine hydrogen chloride (HCl) nail lacquer wre investigated by comparison with vehicle control and 1% terbinafine cream
What is the current status of trial NCT00691184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2005-02. Estimated completion is 2005-12.
What conditions does trial NCT00691184 study?
This clinical trial studies the following conditions: Onychomycosis/Onycholysis and Tinea Pedis.
What interventions are being tested in trial NCT00691184?
The interventions under investigation include: Placebo (DRUG), Terbinafine Hydrochloride (DRUG), Terbinafine (DRUG).
Who is sponsoring clinical trial NCT00691184?
This trial is sponsored by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00691184 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.